{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:13:57Z","timestamp":1760573637001,"version":"build-2065373602"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016308","name":"Wuxi Health and Family Planning Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The 5-year overall survival of hepatocellular carcinoma (HCC) is still poor. Since glypican-3 (GPC3) is highly expressed in most HCC but not in healthy or non-malignant livers, it may become an ideal therapeutic target for HCC. Thus, this study aimed to construct a dynamic nomogram based on contrast-enhanced computed tomography (CT) radiomics for predicting GPC3 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The medical data of consecutive HCC patients from Nanjing Drum Tower Hospital (from January 2020 to August 2023) were retrospectively reviewed. Based on the immunohistochemistry analysis, GPC3-positive was defined as a positive cell rate \u2265 10% (2+ and 3+). The 3D Slicer software and PyRadiomics were used to extract radiomics features on the arterial phase (AP) and venous phase (VP). A radiomics score (Radscore) was constructed using the most predictive features identified by the least absolute shrinkage and selection operator (LASSO) regression analysis. Univariate and multivariate analyses were performed to screen clinical risk factors associated with GPC3-positive. Finally, the Radscore and clinical risk factors were incorporated using logistic regression classification to construct a nomogram.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>181 HCC patients were included according to the inclusion criteria. Among them, 106 were GPC3-positive, and 75 were GPC3-negative. Five radiomics features were finally screened, including three AP and two VP features. The nomogram model combining clinical risk factors (alpha-fetoprotein [AFP] \u2265 10 ng\/mL, hepatitis B virus surface antigen [HBsAg]-negative, and age) and the Radscore (area under the receiver operating characteristic curve [AUROC] = 0.794) was superior to the clinical (AUROC = 0.724) and radiomics models (AUROC = 0.722), with good consistency in the calibration curve. The decision curve analysis (DCA) demonstrated that the nomogram had the highest net benefit for predicting GPC3-positive. The dynamic nomogram is freely available as a mobile application at <jats:ext-link>https:\/\/zheyuzhou.shinyapps.io\/GPC3nomogram\/<\/jats:ext-link>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Since the intra-tumor heterogeneity of HCC and potential complications brought by liver biopsy, our clinical prediction tool identified GPC3 status satisfactorily and might be helpful in clinical decision-making.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1640697","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:24:45Z","timestamp":1760502285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel dynamic nomogram based on contrast-enhanced computed tomography radiomics for prediction of glypican-3-positive hepatocellular carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Chunlong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaobo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomized, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3895","article-title":"Structural and functional impact of posttranslational modification of glypican-3 on liver carcinogenesis","volume":"83","author":"Schepers","year":"2023","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.4.558","article-title":"Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders","volume":"48","author":"Zhu","year":"2001","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i19.2408","article-title":"Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation","volume":"18","author":"Wang","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12876-023-02729-z","article-title":"A novel predictive model of microvascular invasion in hepatocellular carcinoma based on differential protein expression","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"108337","DOI":"10.1016\/j.compbiomed.2024.108337","article-title":"Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma","volume":"173","author":"Bo","year":"2024","journal-title":"Comput Biol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.acra.2022.04.006","article-title":"Radiomics on gadoxetate disodium-enhanced MRI: non-invasively identifying glypican 3-positive hepatocellular carcinoma and postoperative recurrence","volume":"30","author":"Chong","year":"2023","journal-title":"Acad Radiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12957-024-03523-1","article-title":"Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study","volume":"22","author":"Cao","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15950","article-title":"A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study","volume":"11","author":"Zhou","year":"2023","journal-title":"PeerJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000481315","article-title":"Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy","volume":"6","author":"Costentin","year":"2017","journal-title":"Liver Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007369","article-title":"Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study","volume":"11","author":"Wu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2008.11.025","article-title":"Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3","volume":"112","author":"Takai","year":"2010","journal-title":"Acta Histochem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1209814","article-title":"Radiomics nomogram for prediction of glypican-3 positive hepatocellular carcinoma based on hepatobiliary phase imaging","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.3390\/cancers13205180","article-title":"Involvement of kynurenine pathway in hepatocellular carcinoma","volume":"13","author":"Krishnamurthy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i8.1243","article-title":"Predictors of early and late hepatocellular carcinoma recurrence","volume":"29","author":"Nevola","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.102964","article-title":"RNA nanotherapeutics for hepatocellular carcinoma treatment","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14497","article-title":"Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis","volume":"111","author":"Taniguchi","year":"2020","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0000000000001149","article-title":"Preliminary computed tomography radiomics model for predicting pretreatment CD8+ T-cell infiltration status for primary head and neck squamous cell carcinoma","volume":"45","author":"Wang","year":"2021","journal-title":"J Comput Assist Tomogr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/biology11030468","article-title":"Radiomics metrics combined with clinical data in the surgical management of early-stage (cT1-T2 N0) tongue squamous cell carcinomas: A preliminary study","volume":"11","author":"Committeri","year":"2022","journal-title":"Biol (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1053\/j.gastro.2022.06.066","article-title":"Radiomics-based machine-learning models can detect pancreatic cancer on prediagnostic computed tomography scans at a substantial lead time before clinical diagnosis","volume":"163","author":"Mukherjee","year":"2022","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2013.02.014","article-title":"Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection","volume":"154","author":"Fu","year":"2013","journal-title":"Surgery"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2827","article-title":"Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway","volume":"46","author":"Wu","year":"2015","journal-title":"Int J Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2021.02.005","article-title":"The growth rate of hepatocellular carcinoma is different with different TNM stages at diagnosis","volume":"20","author":"Gao","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2011.288","article-title":"The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis","volume":"147","author":"Su","year":"2012","journal-title":"Arch Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000119","article-title":"A commentary on \u2018Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study\u2019 (Int J Surg 2022;105:106843)","volume":"109","author":"Zhou","year":"2023","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41421-023-00563-x","article-title":"Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma","volume":"9","author":"He","year":"2023","journal-title":"Cell Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3724\/zdxbyxb-2023-0483","article-title":"Combination of serum alpha-fetoprotein, PIVKA-II; and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis","volume":"53","author":"Song","year":"2024","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"B43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5604\/01.3001.0012.7863","article-title":"Performance of serum glypican 3 in diagnosis of hepatocellular carcinoma: A meta-analysis","volume":"18","author":"Xu","year":"2019","journal-title":"Ann Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21825","article-title":"The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2","volume":"46","author":"Morford","year":"2007","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2174\/0115734056277475240215115629","article-title":"Radiomic analysis of contrast-enhanced CT predicts glypican 3-positive hepatocellular carcinoma","volume":"20","author":"Sun","year":"2024","journal-title":"Curr Med Imaging"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087120","article-title":"Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma","volume":"9","author":"Gong","year":"2014","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2010.10.004","article-title":"Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma","volume":"15","author":"Yan","year":"2011","journal-title":"Ann Diagn Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1640697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:24:46Z","timestamp":1760502286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1640697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":47,"alternative-id":["10.3389\/fonc.2025.1640697"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1640697","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1640697"}}